TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and ...
The research study will seek to enroll 100 patients and evaluate patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% Cannabidiol (“CBD”) and 1% CBG on arthritis including ...
Avicanna (AVCNF) announced the initial delivery of its proprietary topical products into Europe as a part of the previously announced exclusive supply agreement with a multinational pharmaceutical ...
Avicanna said on Monday an exclusive supply agreement for its two proprietary topical products with a multinational pharmaceutical company. The deal is expected to make Avicanna’s products available ...
The CBG Transdermal Gel is a part of Avicanna’s RHO Phyto formulary of medical products, which includes proprietary oral, sublingual, and topical products containing a range of cannabinoids. The gel ...
(MENAFN- GlobeNewsWire - Nasdaq) The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation TORONTO, April 10, 2024 (GLOBE NEWSWIRE) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results